Does Xintian Pharmaceutical produce pig medicine?

Xintian Pharmaceutical does not produce pig medicine. Xintian Pharmaceutical produces Chinese patent medicines for human consumption.

Xintian Pharmaceutical Co., Ltd., founded in 1995, is a well-known brand in Chinese patent medicine production industry. Mainly engaged in the research and development, production and sales of Chinese patent medicine products for urinary system diseases/gynecological diseases/diseases with complex causes. The leading products are Ningmitai Capsule/Kuntai Capsule/Sophora Flavescentis Gel/Spica Prunellae Oral Liquid.

Guiyang Xintian Pharmaceutical Co., Ltd. was established in August, 1995, and listed on the SME board of Shenzhen Stock Exchange in May, with the stock code of 2019,2065438. The stock is called Xintian Pharmaceutical for short, and the stock code is 002873. The company belongs to the Chinese patent medicine production industry in the pharmaceutical manufacturing industry. It has eight GMP-certified production lines for hard capsules, mixtures, granules, gels, tablets, syrups, liquors and lotions, as well as two production lines for Chinese herbal pieces, line A and line B. It is mainly engaged in the research, development, production and sales of Chinese patent medicine products for diseases with complicated causes such as urinary system diseases and gynecological diseases, and provides patients with safe and effective products.

At present, the company's products are 1 1, and the leading products are Ningbitai capsule, Kuntai capsule, Sophora flavescens gel and Prunella vulgaris oral liquid. The company arranges R&D activities according to the requirements of "production generation, reserve generation and development generation". After more than ten years of development, the company's research and development work has accumulated to a certain extent, which can fully meet the company's new product launch needs. At present, the company is producing 1 1 products, of which 4 products are mainly produced at present, and 7 products are planned to be converted from small batch production to large batch production in the future; Two varieties have been registered and approved for production in the future. Rich variety reserves provide a guarantee for the company's rapid development in the future.

The company has always attached importance to R&D, and regards R&D capability as one of the main factors for the company to achieve sustainable development and an important part of the company's core competitiveness. At present, the company has 40 invention patents, 1 utility model patent 1 and 5 appearance patents. Obtained 1 1 national new drug certificates and 54 drug approval numbers.

In recent years, on the basis of accurately grasping the direction of national medical reform and the development trend of Chinese patent medicine sales, the company adheres to the principle of "sales service, promotion specialization and product quality improvement" and vigorously strengthens the construction of its own marketing management system to adapt to the new situation that the company's leading products enter the national medical insurance catalogue and the national essential drugs catalogue. Secondly, the manager responsibility system should be implemented in each regional market, and the professional division of labor should be implemented for marketing personnel to further strengthen the depth of academic promotion and service marketing.

Through professional academic promotion, the company has improved the trust of clinical medical staff in the company and the company's drugs, effectively maintained the relationship between the company, pharmaceutical commercial companies and hospitals, and combined with the professional and stable marketing team formed by the company over the years, the company's marketing advantages are more prominent.

By the end of 20 18 and 12, the company had a sales team of more than 800 people and established more than 100 regional offices in 30 provinces, autonomous regions and municipalities directly under the central government. The above prescription drug products cover more than 10000 hospitals at or above the county level, including more than 1600 tertiary hospitals. OTC products cover more than 600 pharmaceutical chain companies and more than 57,000 stores, and have established stable business relations with the headquarters of more than 370 domestic pharmaceutical chain companies.